UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 177 filers reported holding UNIQURE NV in Q4 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $307 | -93.1% | 45,737 | -88.2% | 0.00% | -91.7% |
| Q2 2023 | $4,459 | -52.3% | 388,065 | -16.4% | 0.04% | -53.2% |
| Q1 2023 | $9,349 | +41.3% | 464,217 | +59.0% | 0.08% | -19.8% |
| Q4 2022 | $6,617 | -99.8% | 291,887 | +72.0% | 0.10% | +128.6% |
| Q3 2022 | $3,183,000 | +90.1% | 169,673 | +88.9% | 0.04% | +100.0% |
| Q2 2022 | $1,674,000 | +133.1% | 89,831 | +159.3% | 0.02% | +200.0% |
| Q4 2021 | $718,000 | -23.7% | 34,637 | +17.9% | 0.01% | -46.2% |
| Q3 2021 | $941,000 | -61.7% | 29,390 | -63.2% | 0.01% | -51.9% |
| Q2 2021 | $2,458,000 | +520.7% | 79,810 | +578.5% | 0.03% | +350.0% |
| Q1 2021 | $396,000 | -45.2% | 11,762 | -41.2% | 0.01% | -14.3% |
| Q4 2020 | $722,000 | +85.1% | 19,990 | +88.9% | 0.01% | -12.5% |
| Q3 2020 | $390,000 | -87.9% | 10,583 | -85.2% | 0.01% | -90.5% |
| Q2 2020 | $3,220,000 | +1300.0% | 71,469 | +1121.9% | 0.08% | +950.0% |
| Q3 2019 | $230,000 | -89.3% | 5,849 | -78.6% | 0.01% | -90.6% |
| Q2 2019 | $2,140,000 | – | 27,389 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |